Memphasys Reproductive Biotechnology

A pivotal clinical study of the Felix™ System has now been presented to a major scientific and clinical audience for the first time. At the Fertility Society of Australia and New Zealand 2026 Annual Conference in Canberra, A/Prof Hassan Bakos PhD MBA presented results from the multi-centre study involving 103 couples across 10 Monash IVF Group centres. The study found Felix™: • achieved a significantly higher Embryo Utilisation Rate than density gradient centrifugation - 58.8% compared with 49.1% • delivered a comparable result to swim-up • was preferred to density gradient centrifugation by 100% of participating clinicians These findings formed part of the clinical evidence supporting Felix™ achieving CE Mark certification. Memphasys has since secured regulatory access across Europe, Australia and the United Kingdom, more than A$3 million in contracted minimum revenue during FY2026 and a further A$350,000 commercial agreement in Poland. Our collaboration with Monash IVF Group has also progressed from a decade-long scientific relationship and pivotal clinical trial to a 12-month exclusive national supply agreement for Felix™ in Australia. This presentation provides further clinical evidence to support engagement with fertility clinics, embryologists and laboratory decision-makers as Memphasys works to convert its growing portfolio of commercial agreements into product adoption and recurring cartridge revenue. Read the full ASX announcement 👇 David Tasker Marjan Mikel Mathew Watkins Lynx Advisors Pty Ltd Chapter One Advisors Alex Baker Colin Jacoby Joe Durak #Memphasys #FelixSystem #ReproductiveHealth #Fertility #IVF #MedTech #Biotechnology #ASX

We are proud to see the Felix™ System recognised by Monash IVF Group as part of the important research presented at FSANZ 2026. A/Prof Hassan Bakos PhD MBA shared findings from a large, multi-centre prospective randomised study evaluating Felix™, conducted in partnership with Monash IVF Group. The study demonstrated strong embryology outcomes and highlighted the potential of Felix™ to support assisted reproductive treatment. The presentation comes at an important time in our long-standing relationship with Monash IVF Group. In June, Memphasys announced a 12-month exclusive national supply agreement for Felix™, beginning with an initial rollout at two Monash IVF clinics and providing a pathway to deployment across its Australian clinic network. We sincerely thank Monash IVF Group for its role as our clinical trial partner and now commercial partner. This collaboration demonstrates how Australian-developed reproductive technology can progress from rigorous clinical evaluation towards broader clinical adoption. #FSANZ2026 #FelixSystem #FertilityCare #IVF #ReproductiveTechnology #AustralianInnovation David Tasker Marjan Mikel Mathew Watkins Joe Durak Lynx Advisors Pty Ltd Chapter One Advisors

Attending the 2026 FSANZ Annual Conference? Join us for the presentation of important new clinical findings from a multi-centre trial involving 10 Monash IVF Group sites. Memphasys Director of Operations, Clinical Partnerships & Growth and University of Newcastle Adjunct Associate Professor, A/Prof Hassan Bakos PhD MBA, will present the latest clinical findings on the Felix™ System - Memphasys’ patented bio-separation technology for selecting high-quality sperm cells for use in assisted reproduction. Presentation: “The Felix™ System generates significantly higher embryo utilisation rates than density gradient centrifugation and comparable rates to swim-up: A multi-centre prospective randomised sibling oocyte trial.” Sunday, 9 August 2.45pm–3.00pm Royal Theatre, National Convention Centre, Canberra The presentation will provide an opportunity to share the trial outcomes with leading fertility clinicians, embryologists and researchers attending FSANZ 2026. We acknowledge Monash IVF Group and the clinical teams across the 10 participating sites for their important contribution to this research. A/Prof Bakos will also chair the “Evolving Standards and Innovations in Male Fertility Care” session from 9.00am–11.00am on Tuesday, 11 August. We look forward to seeing you in Canberra. #FSANZ2026 #MonashIVF #IVF #ART #Embryology #MaleFertility #ReproductiveMedicine #ClinicalResearch #Memphasys #TheFelixSystem Marjan Mikel David Tasker Mathew Watkins John Aitken

Memphasys is expanding the European commercial footprint of the Felix™ System, securing an exclusive commercialisation agreement in Poland with TK Biotech Sp. z o.o. The agreement has a minimum contracted value of approximately A$350,000 (€212,000) over its two-year commercial term, following an initial three-month evaluation and market-introduction period. Key points: - Poland becomes the third European market where Felix™ has secured commercial sales or an agreement, following Italy and the United Kingdom - Contracted quarterly purchase commitments will commence following the evaluation period - TK Biotech brings an established IVF presence, clinic relationships and technical support capabilities across Poland - The opportunity originated through inbound interest and was advanced following meetings at ESHRE 2026 in London Poland’s IVF sector continues to expand, supported by a publicly funded national program that was operating through 58 fertility clinics as at 31 May 2026. This agreement provides another defined pathway from evaluation to recurring revenue as Memphasys works to convert growing international interest in Felix™ into commercial partnerships and sales. Read the full ASX announcement 👇 David Tasker Marjan Mikel Mathew Watkins Hassan Bakos PhD MBA John Aitken Chapter One Advisors Colin Jacoby Alex Baker Jedd Penkethman #Memphasys #FelixSystem #IVF #Fertility #ReproductiveHealth #MedTech #Commercialisation #ASXNews

Memphasys Limited (ASX: MEM) has delivered its second consecutive record revenue quarter, with commercial momentum continuing to build across Australia and key international markets. Revenue for the June quarter reached $150,000, up 34% on the March quarter, taking FY26 revenue to $273,000. The quarter was also the most commercially active in Memphasys’ history, with key progress including: - The Company’s largest Felix™ commercial agreement to date with Monash IVF Group, covering its network of 22 Australian clinics - Four UK IVF groups commencing commercial evaluations, with initial orders already received - New commercial agreements in Vietnam and Thailand, with a combined value of approximately $961,000 - A further 1,000-cartridge order from MENA partner ITL, taking cumulative orders to 1,800 cartridges - More than $3 million in contracted minimum sales, exceeding the Company’s FY26 corporate goal of $2 million Memphasys also reduced quarterly operating cash outflows by 71% compared with the December quarter and finished the period with $1.179 million in cash. With regulatory approvals expected in Vietnam, Turkey and India, existing agreements moving into delivery and customer utilisation continuing to grow, Memphasys enters FY27 with its broadest commercial footprint to date. Read the full Quarterly Activities Report and Appendix 4C 👇 Marjan Mikel David Tasker Mathew Watkins Hassan Bakos PhD MBA John Aitken Lynx Advisors Pty Ltd Joe Durak Chapter One Advisors #Memphasys #ASX #FelixSystem #MedTech #IVF #ReproductiveHealth #Commercialisation

Day 3 at European Society of Human Reproduction and Embryology (ESHRE) Conference ... and the conversations just keep getting better. Yesterday was all about strengthening relationships with customers and commercial partners from across the globe, while welcoming new groups keen to explore how FELIX™ can fit into their fertility workflows. It was especially exciting to spend time with our new commercial partners from Thailand and a key client from Qatar as Memphasys continues to expand its international distribution network. One of the best signs of a successful conference? When people come back. Throughout the day, we welcomed a number of delegates returning for second (and even third!) conversations as discussions moved from introductions to planning the next steps for commercial collaboration. The momentum around FELIX™ continues to build, and there's still more to come from ESHRE and this trip to the UK. Hassan Bakos PhD MBA Marjan Mikel Mathew Watkins David Tasker Lynx Advisors Pty Ltd Joe Durak Chapter One Advisors Hasan Burjaq

Day 2 at European Society of Human Reproduction and Embryology (ESHRE) and the conference has certainly stepped up. With much larger crowds through the exhibition today, the Memphasys booth was busy throughout the day, with plenty of standing-room-only conversations around FELIX™. A key theme today was commercial momentum. It was particularly encouraging to reconnect with existing customers and partners, many of whom spoke about FELIX™ becoming an increasingly routine part of their laboratory workflow. The team also held a number of valuable discussions with potential customers, commercial partners and distributors who are already evaluating FELIX™ and are now looking at the next step towards broader commercial adoption. A strong day of engagement, validation and partnership discussions. 📍 Booth D53b | ESHRE 2026 | London Hassan Bakos PhD MBA Marjan Mikel Mathew Watkins Chapter One Advisors Lynx Advisors Pty Ltd Joe Durak

The doors haven’t even opened yet… and Booth D53b is already attracting plenty of interest. The Memphasys team, led by Hassan Bakos PhD MBA, is busy putting the finishing touches on our stand ahead of the 42nd Annual Meeting of European Society of Human Reproduction and Embryology (ESHRE) in London, and it’s been fantastic to see delegates already stopping by to learn more about FELIX™. If you’re attending ESHRE this week, we’d love to meet you and discuss the latest clinical, regulatory and commercial progress supporting FELIX™ as it continues its global commercial rollout. Whether you’re an embryologist, clinician, fertility specialist, researcher or potential commercial partner, come and say hello. 📍 Booth D53b | ESHRE | London 📅 5–8 July 2026

Memphasys Reproductive Biotechnology will be attending the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London from 5-8 July 2026.   Visit us at Booth D53b to learn more about FELIX™ and hear about the latest clinical, regulatory and commercial milestones supporting its growing adoption across global fertility markets.   Whether you are an embryologist, clinician, fertility specialist, researcher, industry or commercial partner, we welcome the opportunity to connect, exchange insights and discuss the future of fertility care. 📍 Booth D53b | ESHRE | London 📅 5-8 July 2026 #ESHRE2026 #IVF #Fertility #Embryology #ReproductiveMedicine #Memphasys #FELIX

Memphasys has secured another important commercial milestone for Felix™. The Company has executed an exclusive three-year distribution agreement with IVF Envimed Co., Ltd. for the commercialisation of Felix™ across Thailand, one of South-East Asia’s largest IVF markets. Key highlights: • Minimum contracted value of approximately A$430,500 over three years • Initial order received for 100 Felix™ cartridges and 3 consoles • Revenue expected to commence following Thai FDA approval, anticipated within approximately three to six months • Thailand and Vietnam agreements now represent approximately A$1.0 million in minimum contracted South-East Asian revenue • Total FY2026 Felix™ contracted revenues now approximately A$3.0 million • IVF Envimed has relationships with all 110 registered IVF clinics in Thailand This agreement further expands Memphasys’ growing international commercial footprint, with Felix™ agreements now in place across Australia, Europe, the United Kingdom, MENA, India, Japan, Vietnam and Thailand. Memphasys continues to execute its strategy of building a scalable, recurring revenue business through its proprietary single-use Felix™ cartridge model. Read the ASX announcement 👇 David Tasker Marjan Mikel Hassan Bakos PhD MBA John Aitken Mathew Watkins Chapter One Advisors Lynx Advisors Pty Ltd Joe Durak Colin Jacoby Alex Baker Jedd Penkethman #ASX #MEM #Memphasys #Biotech #IVF #MedTech #Healthcare #Commercialisation